EBITDA: Income before interest, taxes, depreciation and amortization.
Tempest Therapeutics, Inc. (TPST) had EBITDA of $-3.53M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.51M |
|
-- |
|
-- |
|
$3.60M |
|
$-3.60M |
|
$0.09M |
|
$-3.51M |
|
$-3.51M |
|
$-3.51M |
|
$-3.51M |
|
$-3.51M |
|
$-3.51M |
|
$-3.60M |
|
|
EBITDA |
$-3.53M |
4.44M |
|
4.44M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$8.10M |
|
$0.68M |
|
$9.03M |
|
$17.13M |
|
$3.52M |
|
-- |
|
$7.26M |
|
$10.78M |
|
$6.35M |
|
$6.35M |
|
$6.35M |
|
4.44M |
|
| Cash Flow Statement Financials | |
$-23.25M |
|
-- |
|
$0.49M |
|
$30.71M |
|
$7.96M |
|
$-22.75M |
|
$2.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-55.33% |
|
-55.33% |
|
-20.50% |
|
-55.33% |
|
$1.43 |
|
$-5.24 |
|
$-5.24 |
|